title: Patient-reported outcomes are superior in patients with Type 2 diabetes treated with liraglutide as compared with exenatide, when added to metformin, sulphonylurea or both: results from a randomized, open-label study.
abstract: OBJECTIVE
  The Liraglutide Effect and Action in Diabetes 6 trial was an open-label trial comparing liraglutide with exenatide as an 'add-on' to metformin and/or sulphonylurea.
  
  
  METHODS
  Patients with Type 2 diabetes were randomized to liraglutide 1.8 mg once daily or exenatide 10 μg twice daily for 26 weeks. This was followed by a 14-week extension phase, in which all patients received liraglutide 1.8 mg once daily.
  
  
  RESULTS
  Patient-reported outcomes were measured in 379 patients using Diabetes Treatment Satisfaction Questionnaire status (DTSQs) and DTSQ change (DTSQc). The change in overall treatment satisfaction (DTSQs score) from baseline at week 26 with liraglutide was 4.71 and with exentaide was 1.66 [difference between groups 3.04 (95% CI 1.73-4.35), P<0.0001]. Five of the six items on the DTSQs improved significantly more with liraglutide than with exenatide (differences: current treatment 0.37, P=0.0093; convenience 0.68, P<0.0001; flexibility 0.57, P=0.0002; recommend 0.49, P=0.0003; continue 0.66, P=0.0001). Patients perceived a greater reduction in hypoglycaemia at week 26 with liraglutide than with exenatide [difference in DTSQc score 0.48 (0.08-0.89), P=0.0193] and a greater reduction in perceived hyperglycaemia [difference 0.74 (0.31-1.17), P=0.0007]. During the extension phase, when all patients received liraglutide, DTSQs scores remained stable in patients who continued on liraglutide and increased significantly (P=0.0026) in those switching from exenatide.
  
  
  CONCLUSIONS
  These results demonstrate significant improvements in patients' treatment satisfaction with liraglutide compared with exenatide.
authors.affiliation: Department of Medicine I, St Josef Hospital, Ruhr University of Bochum Medical School, Gudrunstrasse 56, Bochum, Germany. wolfgang.e.schmidt@ruhr-uni-bochum.de
authors.forename: W E
authors.initials: WE
authors.lastname: Schmidt
authors.forename: J S
authors.initials: JS
authors.lastname: Christiansen
authors.forename: M
authors.initials: M
authors.lastname: Hammer
authors.forename: M J
authors.initials: MJ
authors.lastname: Zychma
authors.forename: J B
authors.initials: JB
authors.lastname: Buse
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001786:Blood Glucose / Q000187:drug effects*; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy*; D004334:Drug Administration Schedule; D005260:Female; D052216:Glucagon-Like Peptide 1 / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000097:blood / Q000187:drug effects*; D006442:Glycated Hemoglobin / Q000187:drug effects*; D006801:Humans; D007003:Hypoglycemia / Q000097:blood / Q000188:drug therapy*; D000069450:Liraglutide; D008297:Male; D008875:Middle Aged; D017060:Patient Satisfaction; D013453:Sulfonylurea Compounds / Q000008:administration & dosage*; D011795:Surveys and Questionnaires; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D001786:Blood Glucose; D052216:Glucagon-Like Peptide 1; D006442:Glycated Hemoglobin; D000069450:Liraglutide; D013453:Sulfonylurea Compounds